리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 08월
페이지 정보:영문 188 Pages
라이선스 & 가격 (부가세 별도)
한글목차
혈우병 B 세계 시장은 2030년까지 64억 달러에 도달
2023년에 38억 달러로 추정되는 혈우병 B 세계 시장은 분석 기간 2023-2030년에 CAGR 7.8%로 성장했으며 2030년에는 64억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 중등증은 CAGR 7.7%로 성장을 지속하고, 분석 기간 종료 시 27억 달러에 달할 것으로 예측됩니다. 경증 중증도 질환 부문의 성장률은 분석 기간 동안 CAGR 8.8%로 추정됩니다.
미국 시장은 9억 8,910만 달러로 추정, 중국은 CAGR 7.5%로 성장 예측
미국의 혈우병 B 시장은 2023년 9억 8,910만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023년부터 2030년의 분석 기간에 CAGR 7.5%로 성장을 지속하여 2030년에는 10억 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 7.2%와 6.7%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 6.3%로 성장할 것으로 예측됩니다.
세계의 혈우병 B 시장 동향과 촉진요인 정리
크리스마스 병으로도 알려진 혈우병 B는 혈액 응고에 필수적인 단백질 인 IX 인자의 결핍으로 인한 드문 유전성 출혈 질환입니다. 이 질환은 X 연쇄성 열성 유전으로 인해 주로 남성에게 발병하며 여성은 보통 보인자입니다. 혈우병 B의 중증도는 다양하며, 증상은 경증에서 심한 출혈 에피소드까지 있으며, 종종 부상과 수술이 방아쇠가됩니다. 관절과 근육으로의 자연 출혈은 일반적인 합병증이며, 적절하게 관리되지 않으면 통증, 부종 및 장기 관절 손상을 유발합니다. 진단은 IX 인자 활성을 측정하는 혈액 검사에 의해 결정되며, 유전자 검사를 통해 보인자를 확인하고 가족 계획을 결정하는 데 도움이 될 수 있습니다. 치료는 보통 유전자 재조합 혈액 응고 인자 IX 제제 또는 혈장 유래 혈액 응고 인자 IX 제제를 정기적으로 주입하고 출혈 에피소드를 예방 및 제어함으로써 이환자의 QOL을 크게 개선합니다.
의학 연구의 진보는 인자 제제의 관리와 이해를 현저하게 향상시켰습니다. 유전자 치료는 혈액 응고 인자 IX 유전자의 기능적 사본을 간으로 보내고, 필요한 혈액 응고 인자를 생산함으로써 일회성 치유를 목표로 하는 유망한 치료법으로 등장했습니다. 초기 임상시험은 유망한 결과를 얻었고, 환자는 지속적인 수준의 인자 IX 활성을 얻었고 출혈 에피소드는 크게 감소했습니다. 또한, 투여 횟수가 적은 반감기가 연장된 혈액응고 IX인자 제제가 개발되어 치료요법의 편리성과 어드히어런스가 향상되었습니다. 이러한 기술 혁신은 진단기술의 향상과 종합적인 케어 프로그램과 함께 혈우병 B 관리의 상황을 일변시키고 개인이 보다 활동적이고 충실한 생활을 보낼 수 있도록 하고 있습니다.
혈우병 B 치료 시장의 성장은 여러 요인에 의해 견인됩니다. 유전자 치료 및 반감기 연장 응고 인자 제제와 같은 기술의 진보는 더욱 효과적이고 편리한 치료법을 제공합니다. 혈우병 B의 유병률 증가는 인지도와 진단률의 향상과 함께 치료를 요구하는 환자층을 확대하고 있습니다. 또한 신흥국의 건강 관리 인프라 개선 및 전문 의학에 대한 액세스도 시장 성장에 기여합니다. 게다가 환자 지원 단체와 교육 이니셔티브는 조기 진단과 치료의 충동을 촉진하는데 중요한 역할을 합니다. 개인의 유전자 프로파일에 맞추어 치료를 실시하는 맞춤형 의료로의 시프트도, 치료의 효능과 안전성을 높이는 중요한 촉진요인이 되고 있습니다. 제약기업이 연구개발에 투자하는 가운데, 신규 치료제의 파이프라인은 증가의 길을 따라가고 있으며, 혈우병 B의 관리에 있어서의 한층 더 진보가 기대되고 있습니다.
조사 대상 기업 예(전 53건)
Bayer AG
Be Biopharma, Inc.
Centessa Pharmaceuticals Plc
CSL
Freeline Therapeutics
Grifols USA, LLC
Intellia Therapeutics, Inc.
LFB Biotechnologies
Medexus Pharma, Inc.(IXINITY)
novoMEDLINK
Pfizer, Inc.
Spark Therapeutics, Inc.
Swedish Orphan Biovitrum AB(Sobi)
Takeda Pharmaceutical Company
uniQure NV;
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
JHS
영문 목차
영문목차
Global Hemophilia B Market to Reach US$6.4 Billion by 2030
The global market for Hemophilia B estimated at US$3.8 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Moderate Severity Disease, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Mild Severity Disease segment is estimated at 8.8% CAGR over the analysis period.
The U.S. Market is Estimated at US$989.1 Million While China is Forecast to Grow at 7.5% CAGR
The Hemophilia B market in the U.S. is estimated at US$989.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.
Global Hemophilia B Market - Key Trends and Drivers Summarized
Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by a deficiency of factor IX, a protein essential for blood clotting. This condition primarily affects males due to its X-linked recessive inheritance pattern, with females typically being carriers. Hemophilia B can vary in severity, with symptoms ranging from mild to severe bleeding episodes, often triggered by injuries or surgeries. Spontaneous bleeding into joints and muscles is a common complication, leading to pain, swelling, and long-term joint damage if not properly managed. The diagnosis is confirmed through blood tests that measure factor IX activity, and genetic testing can identify carriers and inform family planning decisions. Treatment usually involves regular infusions of recombinant or plasma-derived factor IX concentrates to prevent and control bleeding episodes, greatly improving the quality of life for those affected.
Advancements in medical research have significantly improved the management and understanding of Hemophilia B. Gene therapy has emerged as a promising treatment option, aiming to provide a one-time cure by delivering functional copies of the factor IX gene to the liver, where it can produce the necessary clotting factor. Early clinical trials have shown encouraging results, with patients achieving sustained levels of factor IX activity and a substantial reduction in bleeding episodes. Additionally, extended half-life factor IX products, which require less frequent dosing, have been developed, offering greater convenience and adherence to treatment regimens. These innovations, along with enhanced diagnostic techniques and comprehensive care programs, are transforming the landscape of Hemophilia B management, enabling individuals to lead more active and fulfilling lives.
The growth in the Hemophilia B treatment market is driven by several factors. Technological advancements, such as gene therapy and extended half-life clotting factor products, are providing more effective and convenient treatment options. The increasing prevalence of Hemophilia B, coupled with greater awareness and diagnosis rates, is expanding the patient pool seeking treatment. Improved healthcare infrastructure and access to specialized care in emerging economies are also contributing to market growth. Furthermore, patient advocacy groups and educational initiatives are playing a crucial role in promoting early diagnosis and treatment adherence. The shift towards personalized medicine, where treatments are tailored to individual genetic profiles, is another key driver, enhancing the efficacy and safety of therapies. As pharmaceutical companies invest in research and development, the pipeline of novel therapies continues to grow, promising further advancements in the management of Hemophilia B.
Select Competitors (Total 53 Featured) -
Bayer AG
Be Biopharma, Inc.
Centessa Pharmaceuticals Plc
CSL
Freeline Therapeutics
Grifols USA, LLC
Intellia Therapeutics, Inc.
LFB Biotechnologies
Medexus Pharma, Inc. (IXINITY )
novoMEDLINK
Pfizer, Inc.
Spark Therapeutics, Inc.
Swedish Orphan Biovitrum AB (Sobi)
Takeda Pharmaceutical Company
uniQure N.V.;
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Hemophilia B - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Breakthroughs in Gene Therapy for Hemophilia B Gains Ground
Global Spending on Healthcare Infrastructure Improves Accessibility to Factor IX Products
Development of Extended Half-life Coagulation Factors Expand Treatment Options
Personalized Approaches to the Treatment of Hemophilia B Gains Momentum
Aging Population with Hemophilia, a Key Demographic Driver of Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Hemophilia B Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Moderate Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Moderate Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Moderate Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Mild Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Mild Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Mild Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Severe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Severe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Severe Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for On-Demand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for On-Demand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for On-Demand Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 23: USA Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: USA Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: USA 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 26: USA Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
CANADA
TABLE 29: Canada Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Canada Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Canada 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 32: Canada Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Canada Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Canada 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
JAPAN
Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 35: Japan Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Japan Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Japan 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 38: Japan Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Japan Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Japan 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
CHINA
Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 41: China Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: China Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: China 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 44: China Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: China Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: China 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
EUROPE
Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 47: Europe Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Hemophilia B by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 50: Europe Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Europe Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Europe 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 53: Europe Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
FRANCE
Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 56: France Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: France Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: France 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 59: France Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: France Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: France 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
GERMANY
Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 62: Germany Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Germany Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Germany 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 65: Germany Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Germany Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Germany 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
ITALY
TABLE 68: Italy Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Italy Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Italy 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 71: Italy Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Italy Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Italy 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
UNITED KINGDOM
Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 74: UK Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: UK Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: UK 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 77: UK Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: UK Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: UK 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Rest of Europe Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Rest of Europe 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Rest of Europe Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Rest of Europe 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Asia-Pacific Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Asia-Pacific 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Asia-Pacific Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Asia-Pacific 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 92: Rest of World Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of World Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of World 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
TABLE 95: Rest of World Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Rest of World Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Rest of World 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
